Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Enlicitide Decanoate

Preclinical

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Heterozygous Familial Hypercholesterolemia (hefh)Recruiting

Heterozygous Familial Hypercholesterolemia (hefh)Preclinical

Recruiting

Timeline

Expected Milestones

Q1 2037

PreclinicalRecruiting

Heterozygous Familial Hypercholesterolemia (hefh)

NCT07058077

Clinical

Trials by Indication[1]

Heterozygous Familial Hypercholesterolemia (HeFH)1 trial

An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants With Heterozygous Familial Hypercholesterolemia

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT07058077·153 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Enlicitide Decanoate. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Enlicitide Decanoate. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: Merck & Co.

Related News